Immunology Trials

How does rituximab compare with newer approved monoclonal antibodies (eculizumab, ravulizumab, inebilizumab, satralizumab) for preventing time to first relapse in AQP4-IgG-positive NMOSD?

How have the diagnosis, treatment, disease activity, and disability of AQP4+NMOSD and MOGAD evolved in France over 15 years?

Do monoclonal antibodies provide equivalent efficacy in AQP4-IgG seropositive versus seronegative NMOSD patients?

What is the long-term safety and efficacy of satralizumab in patients with NMOSD who completed the pivotal SAkuraSky and SAkuraStar phase 3 trials?

Persistent high-level EBNA-1 peptide antibodies across serial samples are a highly specific biomarker for MS versus MOGAD, NMOSD (including AQP4-seronegative cases), and other neuroinflammatory diseas...

What is the optimal duration of maintenance immunomodulatory treatment in MOGAD before discontinuation, and what factors predict post-discontinuation relapse?

What is the optimal duration of maintenance immunomodulatory treatment before discontinuation in patients with MOGAD, and what predicts post-discontinuation relapse?

In this systematic review and meta-analysis of 10 observational studies (1,045 patients, 1,368 attacks; >120 centers, 14 countries), plasmapheresis was associated with clinically meaningful visual and...

In this network meta-analysis of 8 trials, hazard ratio point estimates for time to first relapse numerically favored eculizumab and ravulizumab over rituximab, but all pairwise comparisons were non-s...

In a multicenter international cohort of 103 patients with DS-NMOSD, anti-CD20 therapy (mostly rituximab) was associated with a ~98% lower relapse incidence rate ratio than the pretreatment period and...

Opicinumab 750 mg IV q4w did not meet its primary endpoint (Overall Disability Response Score) at 72 weeks, although a multicomponent CDI endpoint that incorporated SDMT and a prespecified subgroup wi...

In a real-world cohort of 176 patients with NMOSD followed for a median of 9 years, FDA-approved NMOSD-specific therapies (C5 inhibitors, inebilizumab, satralizumab) were substantially more effective ...

In adults with HSV encephalitis, adding IV dexamethasone (10 mg QID x 4 days) to aciclovir did not improve verbal memory at 26 weeks compared with aciclovir alone, but was safe with no increase in CSF...

Does rituximab or dimethyl fumarate better reduce astrocytic injury biomarkers and progression independent of relapse/MRI activity in RRMS?

How do complement inhibitors, anti-CD20, and other DMTs compare in preventing NMOSD relapses in the real world?

Comparative Efficacy of DMT in NMOSD

When is it safe to stop immunotherapy in MOGAD, and who relapses after discontinuation?

Treatment Discontinuation in MOGAD

Does adding long-term mycophenolate mofetil (MMF) maintenance therapy to first-line treatment reduce relapse rates and improve outcomes in patients with newly diagnosed anti-NMDA receptor encephalitis compared to first-line treatment alone?